Amgen’s Amjevita takes on AbbVie’s top-selling biotech treatment after fights over how long its patents last

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News Corp Sales Rise on Real Estate, Book Publishing, Media Gains

News Corp NWS 0.54% reported a 13% increase in its quarterly revenue,…

Young people are driving the latest Covid-19 surge

They’re young, they’re restless, and across the United States they’re driving the…

Slaoui Fired From Startup’s Board Over Sexual Harassment Allegations

Moncef Slaoui, a veteran pharmaceuticals executive who helped lead the U.S. government’s…

Swimmer sacrificed his Olympic dream after brutal military coup

SYDNEY — Win Htet Oo has dreamed about competing in the Olympics…